We are live on ! Find out more
ICM

Invenomic Capital Management Portfolio holdings

AUM $1.67B
1-Year Est. Return 1.43%
This Fund
S&P 500
This Quarter Est. Return
+1.91%
1 Year Est. Return
-1.43%
3 Year Est. Return
-6.61%
5 Year Est. Return
-27.23%
10 Year Est. Return
AUM
$1.67B
AUM Growth
-$505M
Cap. Flow
-$520M
Cap. Flow %
-31.03%
Top 10 Hldgs %
29.21%
Holding
171
New
21
Increased
23
Reduced
68
Closed
55

Top Sells

Rank Stock Value
1
CHRD icon
Chord Energy
CHRD
+$73.2M
2
TFX icon
Teleflex
TFX
+$52.2M
3
AKAM icon
Akamai
AKAM
+$46.6M
4
RNG icon
RingCentral
RNG
+$30.2M
5
HAE icon
Haemonetics
HAE
+$28.8M

Sector Composition

Rank Sector Weight
1 Technology 32.19%
2 Healthcare 19.57%
3 Industrials 14.44%
4 Consumer Discretionary 10.33%
5 Communication Services 7.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QS icon
101
QuantumScape Corp
QS
$3.45B
$2.22M 0.13%
293,708
-68,647
-19% -$515K
CENTA icon
102
Central Garden & Pet Co Class A
CENTA
$2.37B
$2.16M 0.13%
55,760
-395,568
-88% -$13.8M
HURC icon
103
Hurco Companies Inc
HURC
$149M
$2.08M 0.12%
90,967
-25,761
-22% -$465K
RGP icon
104
Resources Connection
RGP
$146M
$2.03M 0.12%
476,710
-131,105
-22% -$551K
GETY icon
105
Getty Images
GETY
$107M
$1.99M 0.12%
2,316,030
-745,164
-24% -$645K
FOXF icon
106
Fox Factory Holding Corp
FOXF
$864M
$1.93M 0.12%
+114,060
New +$1.99M
MMS icon
107
Maximus
MMS
$3.13B
$1.83M 0.11%
+34,026
New +$2.12M
EGHT icon
108
8x8 Inc
EGHT
$287M
$1.4M 0.08%
818,755
-1,102,420
-57% -$2.22M
MDY icon
109
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$26.4B
$561K 0.03%
797
DAVA icon
110
Endava
DAVA
$170M
$408K 0.02%
144,240
-566,105
-80% -$2.09M
TLT icon
111
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$46.8B
$302K 0.02%
3,500
ASHR icon
112
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.56B
$271K 0.02%
7,388
CALF icon
113
Pacer US Small Cap Cash Cows 100 ETF
CALF
$3.95B
$244K 0.01%
4,822
LEXX icon
114
Lexaria Bioscience
LEXX
$17.1M
$194K 0.01%
23,046
-6,441
-22% -$69.8K
AVD icon
115
American Vanguard Corp
AVD
$64.6M
$177K 0.01%
63,349
-353,491
-85% -$960K
UFI icon
116
UNIFI
UFI
$139M
$120K 0.01%
25,252
-375,595
-94% -$1.49M
ACHC icon
117
Acadia Healthcare
ACHC
$2.66B
-1,182,331
Closed -$27.7M
AKAM icon
118
Akamai
AKAM
$15.4B
-405,632
Closed -$46.6M
ALIT icon
119
Alight
ALIT
$374M
-101,143
Closed -$1.18M
DCH
120
Dauch Corp
DCH
$1.5B
-556,876
Closed -$3.3M
BDC icon
121
Belden
BDC
$4.5B
-28,440
Closed -$3.27M
BL icon
122
BlackLine
BL
$1.92B
-235,012
Closed -$8.7M
CART icon
123
Maplebear
CART
$11.7B
-255,043
Closed -$9.55M
CHRD icon
124
Chord Energy
CHRD
$7.99B
-515,084
Closed -$73.2M
COP icon
125
ConocoPhillips
COP
$157B
-146,220
Closed -$19.3M

Similar funds

Invenomic Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Invenomic Capital Management held 171 positions worth $1.67B, down 23% from $2.18B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Invenomic Capital Management withdrew a net $520M in Q2 2026, closing 55 positions and reducing 68 holdings. Its most notable exit was Chord Energy, an estimated $73.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Invenomic Capital Management opened a new position in Charter Communications worth $40.2M.

  • Invenomic Capital Management's largest Q2 2026 buy was Charter Communications: 282,416 shares worth $40.2M.
  • Invenomic Capital Management added most to Universal Health Services in Q2 2026, an estimated $39.4M increase.
  • Invenomic Capital Management's biggest Q2 2026 reduction was Haemonetics, cutting an estimated $28.8M.
  • Invenomic Capital Management fully exited Chord Energy in Q2 2026, selling an estimated $73.2M.
  • Invenomic Capital Management's ten largest holdings make up 29% of its $1.67B portfolio in Q2 2026.
  • Invenomic Capital Management opened 21 new positions and closed 55 in Q2 2026.
  • Invenomic Capital Management's portfolio value fell 23% quarter-over-quarter to $1.67B.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.